Background Millions of people worldwide suffer from hepatitis C, which can lead to severe
liver disease, liver cancer, and death. Direct‐acting antivirals (DAAs), eg sofosbuvir, are …

One of the most exciting developments in antiviral research has been the discovery of the
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …

Chronic hepatitis C infection affects millions of people worldwide and confers significant
morbidity and mortality. Effective treatment is needed to prevent disease progression and …

Hepatitis C virus (HCV) mainly replicates in the cytoplasm, where it easily establishes
persistent infection, resulting in chronic hepatitis, liver cirrhosis, and hepatocellular …

Over the past two decades, ribavirin has been an integral component of treatment for
hepatitis C virus (HCV) infection, where it has been shown to improve the efficacy of …

Background Modelling suggests that achieving the World Health Organization's elimination
targets for hepatitis C virus (HCV) is possible by scaling up use of direct-acting antiviral …

Abstract Background and Aim Interferon‐free direct‐acting antiviral regimens for hepatitis C
virus (HCV) infection have been recently available in Australia, beginning a new era in …

Black race and Hispanic ethnicity were associated with lower rates of sustained virologic
response (SVR) to interferon‐based treatments for chronic hepatitis C virus infection …

Interferon‐free combinations were registered in 2014 and 2015 for the treatment of chronic
HCV infection. As a result, real‐world experience has been gathered in the last year and this …

Disclosure Statement: W. Karnsakul has had a relationship with Gilead as a sponsor for an
open-label, multicenter, multicohort, single-arm study to investigate the safety and efficacy of …